Skip to main content
OpenTrials
Completed

NCT Number: NCT05547204

Impact of Coffeeberry Extract on Skill Performance During Simulated Match Play in Academy Football Players

This study of soccer skill performance has three objectives:

1. Compare effects of coffeeberry (300mg) and placebo ingestion on dribbling speed and precision, passing speed and accuracy, and sprint speed during a full simulated soccer match. 2. Compare effects of coffeeberry (300mg) and placebo ingestion on subjective measures (mental / physical energy and activation-deactivation (feelings or mood) during a full simulated soccer match. 3. Compare effects of coffeeberry (300mg) and placebo ingestion on chlorogenic acid (CGA) and caffeine metabolites in the blood 1-hour post ingestion, and other blood metabolites (glucose/lactate) throughout the simulated soccer match.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Skill Performance Behavior Coffeeberry Effects Motor Activity Soccer Performance

Age range

16 year–28 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

U. Stirling, Health Science and Sport

Stirling, Scotland, FK9 4LA, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provide valid informed consent prior to any study procedure
  • Male soccer players age 16 to 28 years.
  • >= 5-year soccer playing experience
  • >= 1-year regularly soccer training
  • Free of injuries
  • Willing to avoid alcohol in the 48-h period prior to all visits
  • Willing to avoid caffeinated products and apples, berries/cherries for 24-h prior to all visits
  • Willing to record food intake over the 48-h period prior to the first trial and replicate for second trial
  • Willing to abstain from strenuous physical activity for 24-h before all visits

Exclusion criteria

  • Smoking
  • Cardiovascular diseases
  • Diabetes or other metabolic disease • Hypertension (>140/>90 mm Hg)
  • Presence of injuries
  • Major illnesses or surgery in prior 90 days
  • Participation in another clinical trial in the past month

Treatment and study plan

Beverage

Other

Free from added carbohydrates (contain 1g CHO only) and electrolytes are absent.

Primary outcomes

  1. Dribbling speed

    Time frame: Change from pre-dose baseline through end of match 3.5 hours post consumption at multiple intervals each half of match

    m/sec, increase would be better. Simulated soccer match in an indoor gym with pre-set targets.

  2. Dribbling precision

    Time frame: Change from pre-dose baseline through end of match 3.5 hours post consumption at multiple intervals each half of match

    Meters, more accuracy would be better. Simulated soccer match in an indoor gym with pre-set targets.

  3. Passing accuracy

    Time frame: Change from pre-dose baseline through end of match 3.5 hours post consumption at multiple intervals each half of match.

    1 to 10 scale, a higher score would be better. Simulated soccer match in an indoor gym with pre-set targets.

  4. Passing speed

    Time frame: Change from pre-dose baseline through end of match 3.5 hours post consumption at multiple intervals each half of match

    km/h, increased passing speed would be better. Simulated soccer match in an indoor gym with pre-set targets.

  5. Sprint speed.

    Time frame: Change from pre-dose baseline through end of match 3.5 hours post consumption at multiple intervals each half of match

    m/sec, increased sprint speed would be better. In indoor gym with marked course.

Secondary outcomes

  1. Blood analyte: Chlorogenic acid (CGA)

    Time frame: Pre-dose baseline, 60 minutes post-dose, half-time, and end of match (3.5 hours)

    mmol/L to evaluate primary outcomes. n.a. for placebo. Capillary blood draw for frozen plasma analysis

  2. Blood analyte: Caffeine metabolites

    Time frame: Pre-dose baseline, 60 minutes post-dose, half-time, and end of match (3.5 hours)

    ug/ml, to evaluate primary outcomes. n.a. for placebo. Capillary blood draw for frozen plasma analysis

  3. Blood analyte: Glucose

    Time frame: Pre-dose baseline, 60 minutes post-dose, half-time, and end of match (3.5 hours)

    mmol/L, more regulated would be better. Capillary blood draw for frozen plasma analysis

  4. Blood analyte: Lactate

    Time frame: Pre-dose baseline, 60 minutes post-dose, half-time, and end of match (3.5 hours)

    mmol/L, lower (delayed rise) would be better. Capillary blood draw for frozen plasma analysis

  5. Rating of perceived exertion (RPE)

    Time frame: Half-time and end of match (3.5 hours)

    By Borg scale, rated 6 to 20, very very light to very very hard. Lower values would be better

  6. Activation-deactivation (feelings or mood)

    Time frame: Pre-dose baseline, 60 minutes post-dose, half-time, and end of match (3.5 hours)

    Checklist of 20 feelings using a 4 point scale from definitely do feel to definitely don't feel. More relaxed feelings or in a better mood would be better.

  7. Mental energy

    Time frame: Pre-dose baseline, 60 minutes post-dose, half-time, and end of match (3.5 hours)

    Visual Analog Scale (VAS), vertical marking on 100 mm horizontal line. Higher energy would be better

  8. Physical energy

    Time frame: Pre-dose baseline, 60 minutes post-dose, half-time, and end of match (3.5 hours)

    Visual Analog Scale (VAS), vertical marking on 100 mm horizontal line. Higher energy would be better

  9. Gut comfort

    Time frame: Pre-dose baseline, 60 minutes post-dose, half-time, and end of match (3.5 hours)

    Visual Analog Scale (VAS), vertical marking on 100 mm horizontal line. No or less nausea, fullness or bloating would be better

  10. Heart rate

    Time frame: Continuous from pre-dose baseline through end of match (3.5 hours)

    By electronic reading. Lower would be better.

  11. Hydration status

    Time frame: Pre-dose baseline and end of match (3.5 hours)

    Urine osmolality in mOsm/kg change in concentration pre- vs. post-exercise

Sponsors and collaborators

Lead sponsor

PepsiCo Global R&D

Industry

Registry information

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Sep 21, 2022
Registry last updated
Mar 16, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.